1. No category

OASIS HLB
Sample Extraction
Products
TM
Setting New Standards for
Solid-Phase Extraction
(SPE) Technology
• Simple and Fast Method
Development
• Enables High Throughput
LC/MS/MS
• Universal Sorbent
• High and Consistent
Recoveries
• Batch-to-Batch
Reproducibility
Speed, Superior Results, Simplicity
Sample preparation is no longer a
bottleneck in lab productivity. Now
SPE can outpace high throughput
techniques such as LC/MS/MS.
Waters designed the new Oasis™ HLB
copolymer* with hydrophilic-lipophilic
balance (HLB), unlike traditional SPE
sorbents (Figure 1). Several major
advantages for SPE result from
our technology.
Undesirable silanol activity, pH
limitations, breakthrough of polar
compounds, irreproducible and low
recoveries, hydrophobic collapse and
stopcock manipulation are now
eliminated. For the first time,
Oasis™ HLB sorbent enables high
performance, robust, reversed-phase
SPE in the 96-well extraction plate
format. Oasis™ HLB sorbent makes
automation of the 96-well format fast,
simple, and rugged. Unique in its
SAMPLE EXTRACTION PRODUCTS
*patent pending
ability to retain both non-polar and
polar compounds and their metabolites, using a single, simple method —
even if the bed runs dry, Oasis™ HLB
sorbent truly sets the new standard
for SPE.
N
O
N-Vinylpyrrolidone
Divinylbenzene
Hydrophilic – Lipophilic Balance
Optimal Properties for Reversed-Phase SPE
Specific Surface Area: 810 m2/g
Average Pore Diameter: 80 Å
Total Pore Volume: 1.3 cm3/g
Average Particle Diameter: 30 µm or 60 µm
Figure 1
Unique Water-Wettable HLB Copolymer
The Oasis™ HLB sorbent is a macroporous
copolymer made from a balanced ratio of two
monomers, the lipophilic divinylbenzene and the
hydrophilic N-vinylpyrrolidone.
Batch-to-Batch
Reproducibility
High and Consistent
Recoveries
Consistent and
continued supply of
Oasis™ HLB sorbent is
assured because we
manufacture it in Waters
own ISO 9002-certified
plant under the cGMP
standard.
Protocols for the
synthesis and processing
of Oasis™ HLB sorbent are
specially designed and
monitored for reproducibility.
Unique, proprietary methods
minimize fines content and render
the sorbent extraordinarily clean.
Each sorbent batch is checked again
at final quality control by ten tests
(Figure 2). A chromatographic
selectivity test measures retention
factors and relative retentions.
Recoveries and relative standard
deviations are reported for an actual
SPE device test using a series of
demanding analytes.
As a result of careful process
design and these stringent quality
controls, a new standard has been
set in batch-to-batch and lot-to-lot
reproducibility for SPE methods
(Figure 3a and 3b). Oasis™ HLB
sorbent uniformity guarantees one
SPE method for years to come.
Oasis™ HLB sorbent provides excellent
recovery, with no breakthrough and
no undesirable secondary retention
mechanisms. Very polar compounds
may be readily isolated at consistent,
high levels, even from pg/mL sample
concentrations, with freedom from
worry about the low recovery problems typical of C18 and other polymer
sorbents (Figure 4a and 4b). Both a
parent compound and its more
polar metabolites can be recovered
simultaneously with a single protocol.
A major cause of poor recovery
in SPE stems from the need to prewet
traditional reversed-phase sorbents with
a water-miscible organic solvent and
keep them wetted — before applying
the aqueous sample matrix. If the
sorbent dries out before loading the
sample, retention of the analytes falls
sharply (Figure 5b). Then, capacity is
severely compromised, and sample
breakthrough can be significant.
Since the Oasis™ HLB sorbent is
water-wettable, it maintains its capability for higher retention and excellent
recoveries of a wider spectrum of
analytes (Figure 5a), even if the
sorbent runs dry. This means that
analysts with many samples to process
no longer need to take extraordinary
steps to keep sorbent beds from drying
out during the critical steps prior to
sample loading.
Whether you are using
20 cartridges on a vacuum manifold
or 96-well plates on automated equipment, the SPE process is greatly
streamlined. In fact, with no means
to monitor individual wells, the water
wettability of Oasis™ HLB sorbent is
essential to the reliable use of the
96-well plate format (Figure 6).
Figure 2
A Certificate of Analysis in Each Box
Product specifications, performance and
sorbent batch test results are reported on
a Certificate of Analysis (COA) that is
included in every package. The COA
details each test’s methodology and
stringent specifications.
Figure 3a and 3b
Exceptional Batch-to-Batch
Performance
High recoveries of four compounds, ranging
from the very polar to lipophilic neutral and
basic compounds, are obtained using the
conditions for the SPE batch test described
on the COA. The recoveries for all compounds were highly consistent, with RSDs
<4% for each analyte, using each of three
different batches of Oasis™ HLB sorbent.
Oasis™ HLB Extraction Cartridges (n=6)
100
2.02
3.66
1.21
2.40 % RSD
80
% Recovery
60
40
20
0
AcetaPropranolol Ranitidine
minophen
Dipropyl
phthalate
Oasis™ HLB Extraction Plates (n=96 wells)
100
0.64
1.48
1.39
2.59 % RSD
80
% Recovery
60
40
20
0
Aceta- Procainamide Doxepin Betamethasone
minophen
Valerate
■ Batch 1
■ Batch 2
■ Batch 3
Polar (acetaminophen), basic (doxepin,
ranitidine) and non-polar, neutral
(betamethasone valerate) drugs were
extracted from saline, using the same
method*. Care was taken to keep all
silica-based and polymer sorbents, except
Oasis™ HLB, wet throughout the extraction
protocol, to avoid any loss of capacity due
to surface drying. Recoveries were low on
C18 and polymer SPE cartridges due to
either breakthrough (acetaminophen) or
excessive retention. Only the Oasis™ HLB
extraction cartridge gave high recoveries
for all drugs.
*The protocol in Figure 7 was used except that
the cartridges were equilibrated with 20 mM
phosphate buffer. Analyses were performed by
HPLC using Symmetry® columns. Recoveries shown
are an average of 3 replicate extractions.
■ Acetaminophen
■ Doxepin
■ Betamethasone valerate
4a: C18-Bonded Silica
100
80
% Recovery
Oasis™ HLB Sorbent Superior to
C18-Bonded Silica (4a) and Other
Polymers (4b)
60
40
20
0
C18 Glass
Fiber Disk
3 cc/15 mg
Oasis™ HLB
C18
C18
PTFE Disk
3 cc/200 mg 3 cc/60 mg
3 cc/13 mg
■ Doxepin
■ Ranitidine
■ Betamethasone valerate
4b: Other Polymers
100
80
% Recovery
Figure 4
60
40
20
0
Figure 5
Effect of Drying on Recovery —
Oasis™ HLB versus C18 Sorbents
100
100
80
80
Procainamide
Acetaminophen
Ranitidine
Propranolol
Doxepin
60
40
Oasis™ HLB
3 cc/60 mg
Figure 5b: C18 Cartridge
% Recovery
* Oasis™ HLB 1 cc/30 mg and 1 cc/100 mg C18
cartridges were conditioned on a Waters vacuum
manifold. When the methanol reached the top of
the upper frit in each cartridge, vacuum was maintained for different times to vary the cartridge drying time. The SPE protocol was then continued (see
Figure 7). The data shown are the average of
three replicate extractions.
Figure 5a: Oasis™ HLB Cartridge
% Recovery
Even if Oasis™ HLB extraction cartridges run
dry after being wet with methanol, high,
reproducible recoveries are obtained from
porcine serum samples spiked with representative pharmaceutical compounds (at
right)*. Recovery of polar compounds, such
as acetaminophen, from C18-bonded silica
cartridges was adversely affected after less
then one minute of drying*.
Polymer B
Polymer C
Polymer A
PS/DVB
PS/DVB
PS/DVB
3 cc/200 mg 3 cc/50 mg 3 cc/100 mg
20
60
40
20
0
0
0
5
Drying Time (minutes)
10
0
4
Drying Time (minutes)
Figure 6
Oasis™ HLB Sorbent Enables High
Performance SPE in 96-Well Plates
Figure 6: 96-Well Plates
100
≤ 35%
≤ 10%
≤ 2%
RSD (n=96)
80
% Recovery
Oasis™ HLB sorbent, in a single 96-well
plate, gives high, reproducible recoveries
for polar and basic drugs, with RSDs ≤2%
(n=96) for each analyte extracted. Plates
containing C18, in either packed bed
or disk format, using the same protocol
(Figure 7), showed low recoveries and high
% RSDs.
60
40
20
0
C18 PTFE Disk
C18
100 mg/well 14 mg/well
Oasis™ HLB
30 mg/well
■ Procainamide
■ Ranitidine
■ Acetaminophen
8
Simple and Fast Method
Development
Sample preparation is required to maximize the quality of analytical results
and to minimize the downtime of
expensive, high-overhead analytical
tools. Oasis™ HLB sorbent now makes
it fast and easy to develop sample
preparation methods that deliver high,
reproducible recoveries. These methods
are much more readily automated
for high sample throughput than are
traditional protocols such as liquidliquid extraction or protein precipitation
(Figure 7).
Unlike traditional C18-bonded silica
sorbents, the Oasis™ HLB copolymer's
reversed-phase adsorption mechanism
Figure 8
Tetracyclines: A Simple, Fast, Effective SPE Method
Tetracyclines are known to interact not only with surface silanols, but also with metals in
silica-based sorbents. Oasis™ HLB copolymer is not complicated by either problem.
Therefore, the generic method (Figure 7) gave high recoveries for the tetracyclines from acidified
porcine serum*. In order to get high and consistent recoveries of tetracyclines with C18 cartridges,
time-consuming method optimization is required.
*HPLC analysis of the extracts was performed on a SymmetryShield™ RP8 column.
Oasis™ HLB Cartridge
1 cc/30 mg (n=6)
Compound
C18 Cartridge
1 cc/100 mg (n=6)
Concentration
(µg/mL in serum)
Recovery
(%)
RSD
(%)
Recovery
(%)
RSD
(%)
2.5
94.8
1.4
40.7
0.82
2.5
104
0.55
67.4
0.44
Minocycline
(CH 3)2N
H
HO
O HO
H
N(CH 3)2
OH
CONH 2
O
O
H
Tetracycline
HO
HO
CH 3 H N(CH 3)2
OH
O
O HO
O
H
CONH 2
Figure 9
Figure 7
A Simple Generic SPE Protocol for
Rapid Method Development
Oasis™ HLB extraction products are versatile
and easy to use. A single, simple protocol
works for a wide range of acidic, basic,
and neutral compounds, with recovery
>85% and RSDs <5% (n=6) in all cases*
(Figure 7). When required, a logical
expansion of this protocol can be used
to meet selectivity and sensitivity goals
(Figures 10 and 11).
*If required, serum may be acidified with
phosphoric acid (20 µL/mL) to disrupt drug-protein
binding.
Achieve High Accuracy and Precision at Low ng/mL Levels
PPD Pharmaco Validated Method for Analysis of Enalapril and
Metabolite Enalaprilat in Human Plasma
% Recovery
n=6
Enalapril
Interday Precision
%CV n=6
Enalapril
% Recovery
n=6
Enalaprilat
Interday Precision
%CV n=6
Enalaprilat
0.5 ng/mL
110.9
3.6
103.6
3.0
5 ng/mL
112.2
4.3
109.4
3.2
80 ng/mL
107.0
1.6
104.5
1.2
Concentration of
Enalaprilat & Enalapril
Internal Std.
91.1
94.3
LOQ=0.25 ng/mL
Solid-phase extraction on Oasis™ HLB extraction cartridges, 3 cc/60 mg, using the general
SPE method (details confidential).
LC/MS/MS Analysis
General SPE Method
Condition
1 mL Methanol
▼
Equilibrate
1 mL Water
Column:
Symmetry® C18 2.1 x 50, mm 3.5 µm
Mobile Phase: Acetonitrile: water, 60:40 containing
0.5 g ammonium acetate and 1.5 mL acetic acid per liter
Enalapril-d5
MB-IS
07 Sm (Mn, 1x1)
100
O
▼
Load
1 mL Spiked Sample
▼
Wash
1 mL 5% Methanol in Water
▼
Elute
1 mL Methanol
▼
Evaporate & Reconstititute
40 °C/200 µL Mobile Phase
N
H
%
MRM of 4 Channels ES +
395.50 > 238.90
HOOC
O
N
O
–11
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
2.75
3.00
Time
Enalaprilat-d5
MB-IS
07 Sm (Mn, 1x1)
MRM of 4 Channels ES +
381.90 > 224.90
HOOC
100
HOOC
N
H
%
N
O
–14
0.25
0.50
0.75
1.00
1.25
1.50
Time
1.75
2.00
2.25
2.50
2.75
3.00
is uncomplicated by the often irreproducible population of surface silanols or
metal impurities (Figure 8). This means
acidic, basic, and neutral compounds,
whether polar or non-polar, can be isolated reproducibly (RSDs <5%) with high
recovery (>85%), using the same, simple SPE protocol. The generic scheme
(Figure 7), which has proven useful
for a wide variety of compound types
may be the only protocol required,
reducing method development time. The
general protocol is especially suited to
LC/MS/MS analysis since this analytical
system simplifies method development
by providing the required selectivity and
sensitivity. PPD Pharmaco (Madison, WI)
validated a simple method for enalapril
and its metabolite enalaprilat using
Oasis™ HLB cartridges and LC/MS/MS;
they achieved high accuracy and
precision at low ng/mL levels (Figure 9).
Figure10
Optimized SPE Method
Condition/Equilibrate
1 mL Methanol/1 mL Water
▼
Load
1 mL Spiked Sample
▼
Wash 1
1 mL 5% Methanol in Water
Acidic Compounds
▼
Basic Compounds
▼
▼
Wash 2
Acid in Methanol/Water
Wash 2
Base in Methanol/Water
▼*
▼*
Elute
Base in Methanol/Water
Elute
Acid in Methanol/Water
*Additional washes may be required
Figure 11
Meeting the Background Challenge of UV Detectors:
Analysis of Tricyclic-Antidepressants in Porcine Plasma
2
4
3
1
Generic SPE Method
5
Meet Selectivity and Sensitivity
Goals
Since the Oasis™ HLB sorbent is stable from pH 1 to 14 and unaffected by
common organic solvents, you may take
advantage of many more available
options for method optimization
(Figure 10). For some applications
cleaner extracts are required to achieve
higher selectivity and sensitivity with
traditional ultraviolet or fluorescence
detectors. Since retention by the
Oasis™ HLB sorbent is very predictable,
a cleaner extract can be achieved by
simply manipulating the organic
concentration and the pH (Figure 11).
This procedure (Figure 10) allows compounds to be retained in a non-ionized
or more lipophilic form in order to
remove interferences with a higher
concentration of organic solvent. The pH
is then changed to allow the compound
to be eluted in the charged or more
hydrophilic state, without increasing
the percent of organic solvent.
6
0.004
AU
Sample
Blank
0
2
1
4
2
6
minutes
4
3
Optimized SPE Method
5
6
0.004
AU
Sample
Blank
0
Column:
Guard Column:
Temperature:
Mobile Phase:
Detection:
Flow Rate:
Injection Volume:
Plasma Extracts:
Spiked at 500 ng/mL
2
4
6
minutes
SymmetryShield™ RP8, 3.5 µm, 4.6 x 75 mm
Sentry™ Guard Column SymmetryShield™ RP8, 5 µm
29 °C
50 mM phosphate, pH 7: methanol (33.6:66.4)
UV at 254 nm
1.4 mL/min
140 µL (Generic Method) or 110 µL (Optimized Method)
1. Nordoxepin
2. Nortriptyline
3. Doxepin (IS)
4. Imipramine
5. Amitriptyline
6. Trimipramine
Details of Optimized Method
Wash 1: 2% ammonium hydroxide in 5% methanol
Wash 2: 2% ammonium hydroxide in 65% methanol
Wash 3: 2% acetic acid in 5% methanol
Elute: 65% methanol in water or omit wash 3 and elute with 2% acetic acid in 65% methanol
Universal Sorbent
With Oasis™ HLB extraction cartridges
and plates, you can isolate a wider
range of acidic, basic and neutral
compounds with one SPE sorbent,
using a single, simple method. The
Oasis™ HLB copolymer, designed for
reversed-phase SPE, has proven to be
the closest thing yet to a “universal”
extraction sorbent. Excellent recoveries
and reproducibilities are obtained for
drugs and their metabolites from serum
for a broad range of compounds using
a simple extraction protocol (Figure
12). The universal sorbent simplifies
the automation of high throughput
LC/MS/MS methods with Oasis™ HLB
extraction plates to an extraordinary
degree.
Figure 12
One Simple Procedure: Many Applications
Shown are seventeen drugs with a wide range of polarity, grouped into acid, neutral and base
categories. The samples were spiked at the indicated concentrations in porcine serum, then
extracted with 1cc/30 mg Oasis™ HLB cartridges, using the same SPE method (Figure 7).* All
recoveries, shown as the mean of six replicates, were >90% with RSDs <3.5%, independent of the
nature of the compounds.
*Serum was acidified with phosphoric acid (20 µL/mL) to disrupt drug-protein binding when necessary. HPLC
analysis was performed on Symmetry® columns.
% Recovery
■ Acids
■ Neutrals
■ Bases
Ibuprofen
Naproxen
Salicylic Acid
Sulfadiazine
Sulfamerazine
Acetaminophen
Theobromine
Paraxanthine
Theophylline
Caffeine
High Capacity
When transferring methods
from a C18-bonded phase to
Oasis™ HLB products, keep in mind the
greater capacity of the HLB sorbent
(Figure 13). A 100-200 mg C18
cartridge may be replaced by 30 mg
of Oasis™ HLB sorbent; 200-500 mg
of C18 may be replaced by 60 mg
of Oasis™ HLB sorbent.
Achieve Low Elution Volumes
without Sacrificing Capacity
The high capacity of the
Oasis™ HLB sorbent made it easy to
meet your request for plasma sample
preparation with low elution volumes
without sacrificing performance.
Waters now offers the Oasis™ HLB
96-well solid-phase extraction plates
Procainamide
Ranitidine
Oxycodone
Propranolol
Naltrexone
Salbutamol
Doxepin
0
20
40
60
80
100
Figure 13
Higher Retention Means Greater Capacity, No Breakthrough
Capacity for a given analyte is a function of its retention factor (k) in a specified solvent,* as well
as the surface area and pore structure of the sorbent. The density of Oasis™ HLB sorbent is about
half that of a bonded-silica phase. So with equivalent bed volume, 2–3x more surface area, and
a dramatic increase in k values, HLB sorbent has typically a 3-10x greater capacity than that of
C18-bonded silica.
*Data shown were obtained with two 3.9 x 150 mm columns, each packed with one of the sorbents, operated
under the same conditions: mobile phase: 20 mM potassium phosphate, pH 7.0/methanol (95/5 v/v);
temperature: 30 °C; flow rate: 1.0 mL/min; detection: UV @ 254 nm.
Retention Factor (k) Comparison
C18 Cartridge
H O
O
HO
O
H
N
O
H
N
H3 C
N
CH 3
Oasis™ HLB Cartridge
Salicylic acid
CH 3
N
Theobromine
N
Acetaminophen
OH
HO
O
HO
Catechol
0
50
100
with 10 mg of sorbent in each well.
Since Oasis™ HLB sorbent has 3 to 10
times greater capacity than traditional
silica-based sorbents or the newer
disk-formatted plates, 10 mg of sorbent
has all the capacity you’ll need for
plasma sample preparation, even for
highly polar drugs and metabolites.
At elution volumes less than 150 µL,
the Oasis™ HLB 10 mg/well extraction
plate gives high (>85%) and reproducible recoveries (RSDs <10%) for all
drugs and their metabolites. Because
your drug and its metabolites are
extracted in less than 150 µL of
volume, you can eliminate the time
consuming and tedious evaporation
and reconstitution step from your SPE
method. Just elute and shoot. This
makes Oasis™ HLB products ideally
suited for situations where high
throughput SPE is a requirement
(Figure 14).
With Oasis™ HLB extraction
plates you get high throughput with
reliable and reproducible results fast
enough to keep pace with your
LC/MS/MS systems.
Figure 14
Recovery Comparisons: Oasis™ HLB Plates (10 mg/well) versus Disk
Formatted Plates
Polar drugs (Procainamide, Acetaminophen, Theophylline) are extracted with significantly higher
recoveries using the Oasis™ HLB extraction plate.
Oasis™ HLB Plate (10 mg/well)
Procainamide
Acetaminophen
Theophylline
Dipropyl Phthalate
C18 PTFE Disk
Procainamide
Acetaminophen
Theophylline
Dipropyl Phthalate
0
20
40
60
% Recovery
80
100
Competitive Comparison of Various Sorbents
This table summarizes the experimental results displayed in Figure 4a and 4b.
Sorbent
Standard C18
Thin Disk C18
Polymer A PS/DVB
Polymer B PS/DVB
Polymer C PS/DVB
Oasis™ HLB
Good for
Bases
Good for
Polars
Universal
Sorbent
Low
Swelling
no
yes*
no
no
no
yes
no
no
yes
yes
no
yes
no
no
no
no
no
yes
yes
yes
no
yes
no
yes
* Recovery of doxepin is good only when a volume of methanol greater than 600 µL is used
for elution (see Figure 4 for conditions). With smaller elution volumes typical for such a small
quantity of sorbent, recovery is <50%, a result indicating the problematic interaction of bases
with silanol groups.
Ultrafast On-Line Analysis
The Oasis™ HLB extraction column makes it possible to analyze a
specific drug or metabolite in plasma or serum with an
analysis time of 1.2 minutes per sample, using
LC/MS/MS. The plasma
sample can be
directly injected onto
the column. Direct
determination of the drug or metabolite is
made at concentrations in the range of
5-1000 ng/mL with an intra-assay accuracy
of typically around 5% RSD.
For more information request the Oasis™ HLB extraction column data sheet.
Ordering Information
Description
Oasis
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
Oasis™
™
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
HLB
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Extraction
Cartridge, 1 cc/30 mg
Cartridge, 3 cc/60 mg
Cartridge, 6 cc/200 mg
Cartridge, 6 cc/500 mg LP*
Cartridge, 12 cc/500 mg LP
Cartridge, 20 cc/1 g LP
Cartridge, 35 cc/6 g LP
Column, 1 mm x 50 mm
Column, 1 mm x 50 mm
Plate, 30 mg/96-well
Plate, 30 mg/96-well
Plate, 30 mg/96-well
Plate, 10 mg/96-well
Plate, 10 mg/96-well
Plate, 10 mg/96-well
Quantity
Part Number
100/box
100/box
30/box
30/box
20/box
20/box
10/box
1/box
10/box
1/pkg
3/pkg
9/pkg
1/pkg
3/pkg
9/pkg
WAT094225
WAT094226
WAT106202
186000115
186000116
186000117
186000118
186000119
186000120
WAT058951
WAT058939
186000233
186000128
186000129
186000232
1/box
25/box
50/box
50/box
50/box
50/box
1/pkg
1/pkg
WAT058941
WAT058942
WAT058943
WAT058957
WAT058958
WAT058959
WAT058955
WAT058956
WAT097944
*LP refers to 60 µm particle size.
Accessories for Oasis™ HLB Extration Plate
Extraction Plate Manifold
Disposable Tray Reservoir
Sample Collection Plate 350 µL
Sample Collection Plate 1 mL
Sample Collection Plate 2 mL
Sealing Cap for Collection Plate
Manifold Gasket, top
Manifold Gasket, white
Extraction Plate Manifold Kit A
(includes extraction plate manifold, reservoir tray,
manifold top gasket, sealing cap and 350 µL
collection plate)
Extraction Plate Manifold Kit B
(includes extraction plate manifold, reservoir tray,
manifold top gasket, sealing cap and 1 mL
collection plate)
Extraction Plate Manifold Kit C
(includes extraction plate manifold, reservoir tray,
manifold top gasket, sealing cap and 2 mL
collection plate)
Accessories for Oasis™ HLB Extration Cartridges
Waters Extraction Manifold, 20 position
Without rack, includes 20 needle tips, 25 plugs
and ejector tool
Complete with rack for 13 mm x 75 mm tubes)
Complete with rack for 13 mm x 100 mm tubes)
Complete with rack for 16 mm x 75 mm tubes)
Complete with rack for 16 mm x 100 mm tubes)
Vacuum
Vacuum
Vacuum
Vacuum
Pumps
pump (110 V, 60 Hz)
pump (220 V, 50 Hz)
pump (110 V, 50 Hz)
Visit us on the Internet:
http://www.waters.com
Sales Offices: Austria and Export (Central and
South East Europe, CIS, Middle East, India and India
Subcontinent) (43) 1 8771807
Australia (61) 2 9933 1777
Belgium and Luxembourg (02) 2 7261000
Brazil (55) 11 543 7788
Canada 800 252 4752, CIS 7 095 336 7000
Czech Republic (42) 02 617 11384
Denmark (45) 46 598080
Finland (358) 9 506 4140
France 01 30487200
Germany (49) 6196 40 06 00
Hong Kong (852) 2964 1800
Hungary (36) 1 270 5086
India (91) 80 8371900
Italy (02) 2 27421.1
Japan (81) 3 3471 7191
Malaysia (603) 704 8600
Mexico (525) 524 5414
The Netherlands (0) 76 508 7200
Norway (0) 638 46 050
Peoples Republic of China - (86) 10 65260828
Poland (48) 22 33 4400
Puerto Rico (787) 747 8445, 790 2225
Singapore (65) 339 3301
Spain (34) 933259616
Sweden (0) 8623 0090
Switzerland (41) 62 889 2030
Taiwan (886) 2 706 8766
UK and Ireland (44) 1 923 816700
All other countries: Waters Corporation U.S.A.
508 478 2000/800 252 4752
WAT097945
WAT097946
1/box
WAT200677
1/box
1/box
1/box
1/box
WAT200606
WAT200607
WAT200608
WAT200609
1/box
1/box
1/box
WAT085114
WAT085115
WAT085123
The quality management system of Waters’ manufacturing
facility, Taunton, Massachusetts, complies with the
International Standard ISO 9002 Quality Management
and Quality Assurance Standards. Waters’ quality
management system is periodically audited by the
registering body to ensure compliance.
Waters, Oasis, Symmetry, and SymmetryShield are
trademarks of Waters Corporation
©1998 Waters Corporation, 5/98, WB025-US